Why CRISPR Therapeutics Just Became an Even Better Buy
CRISPR Therapeutics (NASDAQ: CRSP) is a growth stock with a lot of long-term potential. Its gene-editing business could be about to take off if exa-cel obtains approval from the Food and Drug Administration (FDA). What makes gene-editing therapies potential game changers in the healthcare industry is that they have the potential to revolutionize treatment options for diseases.